TIDMINC
RNS Number : 6872B
Incanthera PLC
14 June 2021
14 June 2021
Incanthera plc
("Incanthera" or the "Company")
Annual General Meeting 2021
COVID Update
Incanthera plc (AQSE: INC), the specialist oncology company
focused on innovative technologies in oncology and dermatology,
announces an update to the current Annual General Meeting ("AGM")
arrangements, as announced on 19 May 2021.
Incanthera's AGM is currently due to be held at the offices of
Gateley Plc, Ship Canal House, 98 King Street, Manchester, M2 4WU
at 11:00 a.m. on Wednesday, 23 June 2021.
Announcements made by the Government this week, have identified
Greater Manchester as an area of concern relating to increasing
cases of the COVID-19 Delta variant, and as such travel in or out
of the identified area is discouraged.
Accordingly, the meeting location to host the minimum attendance
necessary to form a quorum (which will be facilitated by the
Company) has been moved from the Greater Manchester area to the
Marriott Hotel, Breadsall Priory, Derby.
The Meeting will focus on the formal business of the meeting
only.
Legislation and government guidance in the United Kingdom
continues to place restrictions on public gatherings and we have
previously advised that Shareholders are not encouraged to attend
the meeting in person. Given the recent new advice on rising cases,
and unnecessary travel, the health and safety of our Shareholders
remains a priority. Accordingly, we regretfully advise that
although we have moved the location of the AGM, we are still
advising shareholders not to attend the meeting in person.
All other details as advised in the Notice of AGM, posted to
Shareholders on 19 May, remain as follows:
In order to ensure that shareholders are able to follow the
proceedings of the AGM, the Company will provide access online
through the Investor Meet Company platform. However, shareholders
will not be able to vote online during the Meeting and are
therefore urged to submit their votes via proxy, if they have not
already done so, as early as possible, electronically or by
post.
These documents are also available, in electronic form, for
download on the Company's website: www.incanthera.com
Shareholders are also invited to submit written questions for
the Board to consider. Questions can be pre submitted in advance of
the AGM via the Investor Meet Company Platform up to 9.00 a.m. on
22 June 2021, being the day before the AGM, or via the Investor
Meet Platform at any time during the AGM itself.
The Board will respond to key questions during the meeting and
will provide such answers on its website thereafter.
Shareholders who wish to attend the AGM online should register
for the event in advance via the following link:
https://www.investormeetcompany.com/incanthera-plc/register-investor
The Board would like to take this opportunity to thank
Shareholders for their understanding and support of the necessary
precautions taken during this time.
For further enquiries:
Incanthera plc
www.incanthera.com
Tim McCarthy, Chairman
tim.mccarthy@incanthera.com +44 (0) 7831 675747
Simon Ward, Chief Executive Officer
simon.ward@incanthera.com +44 (0) 7747 625506
Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com +44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis +44 (0) 20 7213 0880
Broker:
Stanford Capital Partners Ltd
Patrick Claridge/John Howes/Bob Pountney +44 (0) 20 3815 8880
Notes to Editors
Incanthera is a specialist oncology company focused on
innovative technologies in oncology and dermatology . It seeks to
identify and develop innovative solutions to current clinical,
commercially relevant unmet needs, utilising new technology from
leading academic institutions.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers. This has achieved
proof of concept and the Company is now focussed upon delivering
Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics
("ICT") at the University of Bradford and has acquired and
developed a portfolio of specific cancer-targeting therapeutics
through a Pipeline Agreement with the ICT and other corporate
acquisitions.
Incanthera's strategy is to develop each candidate in the
portfolio from initial acquisition or discovery to securing its
future through commercially valuable partnerships at the earliest
opportunity in its development pathway.
For more information on the Company please visit:
www.incanthera.com
@incantheraplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXDZGMVFMNGMZM
(END) Dow Jones Newswires
June 14, 2021 02:00 ET (06:00 GMT)
Incanthera (AQSE:INC)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Incanthera (AQSE:INC)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
